Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases
Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting gl...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Sarajevo
2023-10-01
|
| Series: | Journal of Health Sciences |
| Subjects: | |
| Online Access: | https://www.jhsci.ba/ojs/index.php/jhsci/article/view/2146 |
| _version_ | 1797662251500437504 |
|---|---|
| author | Nahida Srabović Monika Rustemović Čorbić Esmeralda Dautović Aida Smajlović Adaleta Softić Anida Delimehić Jasmina Grapkić Aličić Damir Terzić Emina Hodžić Arnela Šakušić Mujić Ezaneta Merdanović Zerina Sakić Eldina Žunić Mehmed Salkić Aida Ždralić |
| author_facet | Nahida Srabović Monika Rustemović Čorbić Esmeralda Dautović Aida Smajlović Adaleta Softić Anida Delimehić Jasmina Grapkić Aličić Damir Terzić Emina Hodžić Arnela Šakušić Mujić Ezaneta Merdanović Zerina Sakić Eldina Žunić Mehmed Salkić Aida Ždralić |
| author_sort | Nahida Srabović |
| collection | DOAJ |
| description |
Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting glucose (FG) and hemoglobin A1c (HbA1c) in CVD patients.
Methods: The case–control study included 123 patients from Tuzla Canton, Bosnia, and Herzegovina, with a diagnosis of CVD, treated in three health centers: Public Health Center Gračanica, Banovići, and Čelić. Of total patients, 84 were statin users (39 atorvastatin users and 45 rosuvastatin users) and 39 were not. Demographic data, diagnosis, and data of the therapy were taken from the medical records, as well as data of the FG and HbA1c, measured before or within 3 months of the statin therapy introduction. For the same patients, FG and HbA1c were also measured at least 3 months after the introduction of therapy.
Results: Obtained results have shown a significant increase of FG in CVD patients on statin therapy in relation to control (p = 0.034). Comparing the diabetogenic effects of atrovastatin and rosuvastatin, it was found that the HbA1c in patients on atorvastatin therapy was significantly higher comparing to those on rosuvastatain therapy (p = 0.028). The FG was significantly increased (p = 0.027) after atrovastatin therapy. Similar results were obtained in diabetogenic CVD patients, where HbA1c on atorvastatin therapy was significantly higher comparing to HbA1c in those on rosuvastatain therapy (p = 0.039). A significant correlation was found between the increase in FG and HbA1c with the duration of atorvastatin therapy (p = 0.001 and p = 0.033), and between the increase in HbA1c and the duration of rosuvastatin therapy (p = 0.001).
Conclusion: Long-term therapy with high-potency statins, atorvastatin, and rosuvastatin, may increase levels of FG and HbA1c in patients with CVD, where atorvastatin shows more significant effects.
|
| first_indexed | 2024-03-11T18:57:29Z |
| format | Article |
| id | doaj.art-4e0a3641a7624f639c65917f9a0cb52c |
| institution | Directory Open Access Journal |
| issn | 2232-7576 1986-8049 |
| language | English |
| last_indexed | 2024-03-11T18:57:29Z |
| publishDate | 2023-10-01 |
| publisher | University of Sarajevo |
| record_format | Article |
| series | Journal of Health Sciences |
| spelling | doaj.art-4e0a3641a7624f639c65917f9a0cb52c2023-10-10T16:32:47ZengUniversity of SarajevoJournal of Health Sciences2232-75761986-80492023-10-0110.17532/jhsci.2023.2146Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseasesNahida Srabović0Monika Rustemović Čorbić1Esmeralda Dautović2Aida Smajlović3Adaleta Softić4Anida Delimehić5Jasmina Grapkić Aličić6Damir Terzić7Emina Hodžić8Arnela Šakušić Mujić9Ezaneta Merdanović10Zerina Sakić11Eldina Žunić12Mehmed Salkić13Aida Ždralić14Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and HerzegovinaDepartment of SEE Region, Bosnalijek d.d., Sarajevo, Bosnia and HerzegovinaDepartment of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and HerzegovinaDepartment of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and HerzegovinaDepartment of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Gračanica, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Gračanica, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Gračanica, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Gračanica, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Gračanica, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Gračanica, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Banovići, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Banovići, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Banovići, Bosnia and HerzegovinaDepartment of Family Medicine, Public Health Center Čelić, Bosnia and Herzegovina Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting glucose (FG) and hemoglobin A1c (HbA1c) in CVD patients. Methods: The case–control study included 123 patients from Tuzla Canton, Bosnia, and Herzegovina, with a diagnosis of CVD, treated in three health centers: Public Health Center Gračanica, Banovići, and Čelić. Of total patients, 84 were statin users (39 atorvastatin users and 45 rosuvastatin users) and 39 were not. Demographic data, diagnosis, and data of the therapy were taken from the medical records, as well as data of the FG and HbA1c, measured before or within 3 months of the statin therapy introduction. For the same patients, FG and HbA1c were also measured at least 3 months after the introduction of therapy. Results: Obtained results have shown a significant increase of FG in CVD patients on statin therapy in relation to control (p = 0.034). Comparing the diabetogenic effects of atrovastatin and rosuvastatin, it was found that the HbA1c in patients on atorvastatin therapy was significantly higher comparing to those on rosuvastatain therapy (p = 0.028). The FG was significantly increased (p = 0.027) after atrovastatin therapy. Similar results were obtained in diabetogenic CVD patients, where HbA1c on atorvastatin therapy was significantly higher comparing to HbA1c in those on rosuvastatain therapy (p = 0.039). A significant correlation was found between the increase in FG and HbA1c with the duration of atorvastatin therapy (p = 0.001 and p = 0.033), and between the increase in HbA1c and the duration of rosuvastatin therapy (p = 0.001). Conclusion: Long-term therapy with high-potency statins, atorvastatin, and rosuvastatin, may increase levels of FG and HbA1c in patients with CVD, where atorvastatin shows more significant effects. https://www.jhsci.ba/ojs/index.php/jhsci/article/view/2146Cardiovascular diseasefasting glucosehemoglobin A1cstatins |
| spellingShingle | Nahida Srabović Monika Rustemović Čorbić Esmeralda Dautović Aida Smajlović Adaleta Softić Anida Delimehić Jasmina Grapkić Aličić Damir Terzić Emina Hodžić Arnela Šakušić Mujić Ezaneta Merdanović Zerina Sakić Eldina Žunić Mehmed Salkić Aida Ždralić Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases Journal of Health Sciences Cardiovascular disease fasting glucose hemoglobin A1c statins |
| title | Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases |
| title_full | Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases |
| title_fullStr | Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases |
| title_full_unstemmed | Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases |
| title_short | Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases |
| title_sort | comparative study of long term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin a1c in patients with cardiovascular diseases |
| topic | Cardiovascular disease fasting glucose hemoglobin A1c statins |
| url | https://www.jhsci.ba/ojs/index.php/jhsci/article/view/2146 |
| work_keys_str_mv | AT nahidasrabovic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT monikarustemoviccorbic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT esmeraldadautovic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT aidasmajlovic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT adaletasoftic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT anidadelimehic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT jasminagrapkicalicic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT damirterzic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT eminahodzic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT arnelasakusicmujic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT ezanetamerdanovic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT zerinasakic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT eldinazunic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT mehmedsalkic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases AT aidazdralic comparativestudyoflongtermeffectsofatorvastatinandrosuvastatinonfastingglucoseandhemoglobina1cinpatientswithcardiovasculardiseases |